Join our Newsletter
From medical white papers to invite only networking, join our newsletter to stay connected with the world of CRC.
Psychiatry
The CRO
for Psychiatry
Psychiatry drug development is one of the most complex areas in clinical research. Unlike trials with objective lab values or imaging readouts, psychiatry depends on human judgment. Subjective endpoints, fluctuating symptoms, and placebo effects all challenge the ability to detect true treatment signals. High screen failure rates make enrollment unpredictable, while fragile patient engagement demands thoughtful site support and strategies that respect the realities of living with mental health conditions.
For two decades, CRC has been dedicated exclusively to neuroscience, building an unmatched foundation in psychiatry. With experience across 55+ trials in depression, schizophrenia, bipolar disorder, anxiety, and substance use disorders, our team understands the nuances that can slow progress and also possess the skills to design and execute studies that keep signals clear, timelines realistic, and patients engaged.
- Agitation – Schizophrenia & Bipolar
- Alcohol & Substance Use Disorders
- Anxiety Disorders
- Bipolar Disorders
- Major Depressive Disorders
- Obsessive Compulsive Disorder
- Schizophrenia & Schizoaffective Disorders
- Treatment-Resistant Depression
HOW CRC DELIVERS IN
PSYCHIATRY TRIALS
In-House Assessments Expertise That Reduces Placebo Response and Variability
Psychiatry trials are vulnerable to high placebo response and inconsistent ratings across sites. CRC’s embedded assessments team addresses these risks head-on. With targeted rater training, simulation-based certification, and continuous drift monitoring, we strengthen reliability across scales like MADRS, HAM-D, YMRS, and PANSS. This hands-on oversight reduces noise and increases the likelihood of detecting true treatment effects.
Scientific Leadership That Knows Psychiatric Development Firsthand
Our medical and scientific leaders have advanced therapies in depression, schizophrenia, bipolar disorder, and anxiety from first-in-human through pivotal approval. They understand the nuances of psychiatric endpoints, from patient-reported outcomes to functional assessments, and design protocols that balance feasibility with regulatory and scientific rigor. This lived experience allows CRC to anticipate challenges and guide sponsors with proven strategies.
Consistent Teams That Understand the Nuances of Psychiatry Trials
Psychiatry programs are complex and demand steady hands at the helm. CRC’s 86 percent employee retention means the same project teams remain engaged from start-up through closeout. Our staff bring deep familiarity with psychiatric endpoints and site operations, reducing handoff errors and keeping execution consistent. Sponsors benefit from continuity that preserves knowledge and sustains momentum across challenging studies.
Site Relationships That Boost Engagement and Patient Retention
Recruitment and retention are persistent hurdles in psychiatry trials, where stigma, fluctuating symptoms, and long treatment courses can derail progress. CRC’s long-standing partnerships with experienced psychiatry investigators and leading KOLs give sponsors access to sites that understand how to engage patients effectively. These trusted relationships enable us to secure protocol feedback early, identify realistic enrollment pathways, and keep sites motivated.
Proven Impact in
Psychiatry Clinical Development
The proof is in our partnerships. 87% of our sponsors return for new collaborations – a reflection of the trust we build and the results we deliver.
get in touch